Europe Liquid Biopsy Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2024 –2030 |
 Tamanho do mercado (ano base ) | |
 Tamanho do mercado ( Ano de previsão) | |
 CAGR |
% |
| Principais participantes do mercado |
>Mercado europeu de biópsia líquida, por produto (instrumentos, consumíveis e acessórios, serviços e software), tipo de biomaker ( células tumorais circulantes (CTCS) , DNA livre de células circulantes (CFDNA), RNA livre de células, vesículas extracelulares, exossomas e outros ), Tipo de amostra (com base numa amostra de sangue, com base numa amostra de urina, com base numa amostra de saliva e outros fluidos teciduais e outros), tipo analítico (molecular, proteómica e histologia/imagem), tipo de aplicação (aplicações contra o cancro e aplicações não cancerígenas), aplicação clínica (rastreio de rotina, avaliação do doente, seleção da terapêutica, monitorização do tratamento, monitorização da recidiva e outras), tecnologia (análise paralela multigénica e análise de gene único), utilizador final (hospitais, laboratórios de referência, Centros de Diagnóstico, Centros de Investigação e Institutos Académicos e Outros), Canal de Distribuição (Concurso Directo, Distribuidor Terceirizado e Outros) - Tendências do Sector e Previsão para 2030.
Análise e insights do mercado europeu de biópsia líquida
A crescente consciência da tecnologia de diagnóstico avançada na Europa aumentou a procura do mercado. O aumento dos gastos em saúde para melhores serviços de saúde também contribui para o crescimento do mercado. Os principais players do mercado concentram-se em diversos lançamentos e aprovações de serviços durante este período crucial. Além disso, o aumento do avanço de processos e técnicas também contribui para a crescente procura de biópsia líquida.
Espera-se que o mercado europeu de biópsia líquida cresça no ano previsto devido ao aumento dos participantes no mercado e à disponibilidade de serviços avançados. A par disto, os fabricantes estão empenhados na atividade de desenvolvimento para o lançamento de novos serviços no mercado. O crescente desenvolvimento no campo das técnicas avançadas de saúde está a impulsionar ainda mais o crescimento do mercado.
No entanto, dificuldades como a falta de protocolos padronizados e a falta de profissionais qualificados podem dificultar o crescimento do mercado europeu de biópsia líquida no período de previsão.
A Data Bridge Market Research analisa que o mercado europeu de biópsia líquida irá crescer a um CAGR de 15,1% durante o período de previsão de 2023 a 2030.
|
Métrica de reporte |
Detalhes |
|
Período de previsão |
2023 a 2030 |
|
Ano base |
2022 |
|
Anos históricos |
2021 (personalizável para 2015-2020) |
|
Unidades Quantitativas |
Receita em milhões, volumes em unidades, preços em dólares americanos |
|
Segmentos cobertos |
Produto (instrumentos, consumíveis e acessórios, serviços e software), tipo de biomaker (células tumorais circulantes (CTCS), DNA livre de células circulantes (CFDNA), RNA livre de células, vesículas extracelulares, exossomas e outros), tipo de amostra ( sangue Com base numa amostra, com base numa amostra de urina, com base numa amostra de saliva e outros fluidos de tecidos e outros), tipo analítico (molecular, proteómica e histologia/imagem), tipo de aplicação (aplicações contra o cancro e aplicações não oncológicas), aplicação clínica ( Rastreio de rotina, avaliação do doente, seleção da terapêutica, monitorização do tratamento, monitorização da recidiva e outros), tecnologia (análise paralela multigénica e análise de gene único), utilizador final (hospitais, laboratórios de referência, centros de diagnóstico, centros de investigação e Institutos Académicos e Outros), Canal de Distribuição (Concurso Directo, Distribuidor Terceirizado e Outros) |
|
Países abrangidos |
Alemanha, Reino Unido, França, Itália, Espanha, Países Baixos, Rússia, Suíça, Turquia, Bélgica e Resto da Europa |
|
Participantes do mercado abrangidos |
F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, mdxhealth, NeoGenomics Laboratories, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC., Menarini Silicon Biosystems, Sysmex Inostics Inc. e ANGLE plc, entre outros |
Definição de mercado
Uma biópsia líquida é um exame médico que envolve a análise de várias biomoléculas, como ADN, ARN, proteínas e outras substâncias no sangue ou outros fluidos corporais de um paciente, para diagnosticar e monitorizar várias condições médicas, incluindo o cancro. Ao contrário das biópsias tradicionais que envolvem a remoção de amostras de tecido do corpo, uma biópsia líquida não é invasiva e pode fornecer informações de diagnóstico importantes sem a necessidade de cirurgia ou outros procedimentos invasivos. As biópsias líquidas ainda estão numa fase inicial de desenvolvimento, mas são promissoras para melhorar a deteção e o tratamento do cancro e de outras doenças.
Dinâmica do mercado de biópsia líquida na Europa
Esta secção trata da compreensão dos impulsionadores do mercado, vantagens, oportunidades, restrições e desafios. Tudo isto é discutido em detalhe abaixo
Motoristas
- Crescente procura por técnica de biópsia líquida não invasiva
As biópsias líquidas consistem no isolamento de entidades derivadas de tumores, como células tumorais circulantes, ADN tumoral circulante e vesículas extracelulares tumorais, entre outras, presentes nos fluidos corporais dos doentes oncológicos, seguindo-se uma análise dos dados genómicos e proteómicos neles contidos. Os métodos de isolamento e análise de biópsias líquidas têm evoluído rapidamente nos últimos anos, como descrito na revisão, fornecendo mais detalhes sobre características tumorais como mutações, estadiamento tumoral, progressão tumoral, heterogeneidade e evolução génica e clonal, entre outras. As biópsias líquidas de doentes oncológicos abriram novos caminhos na deteção e monitorização contínua, no tratamento baseado na medicina de precisão e no rastreio de marcadores de resistência terapêutica. O diagnóstico não invasivo do cancro oferece uma abordagem mais segura e mais amigável para o doente, resultando numa procura crescente por estes métodos.
- Avanços na medicina de precisão devido à biópsia líquida
A oncologia médica de precisão na gestão clínica do cancro pode ser conseguida através da plataforma diagnóstica denominada “biópsia líquida” (LB). O LB foi reconhecido como uma poderosa abordagem em tempo real para a monitorização molecular desta doença cancerígena dinâmica. Este método utiliza a detecção de Biomakers no sangue para fins prognósticos e preditivos por meios não invasivos, o que num futuro próximo representará uma mudança no paradigma da compreensão da biologia molecular e da heterogeneidade dos tumores. Os avanços na medicina de precisão, alimentados pela utilização de técnicas de biópsia líquida, contribuíram significativamente para a crescente procura de diagnósticos não invasivos do cancro. As técnicas de biópsia líquida, como a análise de ADN tumoral circulante (ctDNA), células tumorais circulantes (CTCs) ou exossomas no sangue ou noutros fluidos corporais, fornecem informações valiosas sobre a composição genética dos tumores, permitindo abordagens de medicina de precisão no tratamento da cancro.
Oportunidade
- Integração de Inteligência Artificial (IA) e aprendizagem automática
As abordagens baseadas em biópsia líquida oferecem muitas novas oportunidades para medir Biomakers moleculares para diagnóstico, prognóstico e monitorização de doenças. A Inteligência Artificial (IA), tal como a aprendizagem automática, e a sua capacidade de identificar assinaturas de estados de doença específicos em dados multiplexados, serão fundamentais para tirar partido da nova informação molecular que os diagnósticos baseados em microchips podem extrair.
Assim, espera-se que a integração da IA e da aprendizagem automática funcione como uma oportunidade para o crescimento do mercado.
- Aumento dos reembolsos e apoio governamental para a biópsia líquida
A adoção da biópsia líquida foi significativamente influenciada pelo apoio governamental. Os governos de todo o mundo implementaram legislação para incentivar a adoção da biópsia líquida porque compreendem como pode melhorar os cuidados prestados aos doentes, reduzir os custos dos cuidados de saúde e promover o avanço da medicina de precisão. A incorporação da biópsia líquida nos programas nacionais de rastreio do cancro ou nas recomendações de tratamento é apenas um exemplo de como isto pode ser feito. Outros exemplos incluem o financiamento para investigação e desenvolvimento de tecnologias de biópsia líquida e o apoio a ensaios clínicos e estudos para produzir provas sobre a sua eficácia terapêutica. Esta assistência governamental ajudou a aumentar o conhecimento, a adoção e a cobertura de reembolso dos testes de biópsia líquida.
Assim, espera-se que o aumento dos reembolsos e do apoio governamental à biópsia líquida atue como uma oportunidade para o crescimento do mercado.
Restrição/Desafio
- Elevado custo dos testes de biópsia líquida
A biópsia líquida é severamente limitada pelo elevado custo. Embora os testes de biópsia líquida sejam promissores para a detecção e monitorização não invasiva de doenças, incluindo o cancro, existem obstáculos relacionados com os custos que podem impedir a sua utilização generalizada.
A necessidade de ferramentas e tecnologias especializadas é um dos maiores obstáculos económicos. Ferramentas caras, incluindo máquinas digitais de PCR, plataformas NGS e sistemas automatizados de processamento de amostras, são frequentemente necessárias para estudos de biópsia líquida. As instalações de saúde mais pequenas e com orçamentos mais apertados podem ter dificuldade em suportar o investimento inicial e os custos de manutenção contínuos associados a estas tecnologias, o que limita a sua capacidade de fornecer testes de biópsia líquida aos doentes.
Assim, espera-se que o elevado custo dos testes de biópsia líquida restrinja o crescimento do mercado.
- Falta de profissionais qualificados para a realização de biópsia líquida
A procura por testes de biópsia líquida está a aumentar devido à sua potencial utilidade clínica na deteção, monitorização e tomada de decisões de tratamento personalizado do cancro. Contudo, pode haver recursos limitados, incluindo pessoal, equipamento e financiamento, para apoiar a implementação de programas de biópsia líquida em instituições de saúde. Isto pode resultar numa escassez de profissionais qualificados que possam realizar testes de biópsia líquida, especialmente em regiões ou ambientes de saúde com recursos limitados.
Assim, espera-se que a falta de profissionais qualificados a realizar biópsias líquidas desafie o crescimento do mercado.
Desenvolvimento recente
- Em janeiro de 2022, a Exact Sciences Corporation anunciou a aquisição da Prevention Genetics, um laboratório de testes genéticos, para complementar o seu portefólio de diagnóstico avançado de cancro e apoiar a sua entrada nos testes hereditários de cancro (HCT).
Âmbito do mercado de biópsia líquida da Europa
O mercado europeu de biópsia líquida está categorizado em nove segmentos notáveis que são produto, tipo Biomaker, tipo de amostra, tipo analítico, tipo de aplicação, aplicação clínica, tecnologia, utilizador final e canal de distribuição. O crescimento entre estes segmentos irá ajudá-lo a analisar os segmentos de crescimento do mercado nas indústrias e fornecer aos utilizadores uma valiosa visão geral do mercado e insights de mercado para os ajudar a tomar decisões estratégicas para identificar as principais aplicações do mercado.
Produto
- Instrumentos
- Consumíveis e acessórios
- Serviços e Software
Com base no produto, o mercado está segmentado em instrumentos, consumíveis e acessórios, serviços e software.
Tipo de Biomaker
- Células Tumorais Circulantes (CTCS)
- DNA livre de células circulantes (CFDNA)
- RNA livre de células
- Exossomos
- Vesículas extracelulares
- Outros
Com base no tipo de biomaker, o mercado está segmentado em células tumorais circulantes (CTCS), ADN livre de células circulantes (CFDNA), RNA livre de células, vesículas extracelulares, exossomas, entre outros.
Tipo de amostra
- Baseado em amostra de sangue
- Baseado em amostra de urina
- Saliva e outros fluidos teciduais com base em amostras
- Outros
Com base no tipo de amostra, o mercado está segmentado em amostras de sangue, amostras de urina, saliva e outros fluidos teciduais, entre outros.
Tipo Analítico
- Molecular
- Proteómica
- Histologia/Imagem
Com base no tipo analítico, o mercado está segmentado em molecular, proteómica e histologia/imagiologia.
Tipo de aplicação
- Aplicações contra o cancro
- Aplicações não oncológicas
Com base no tipo de aplicação, o mercado está segmentado em aplicações oncológicas e aplicações não oncológicas.
Aplicação Clínica
- Triagem de rotina
- Seleção de Terapia
- Monitorização do tratamento
- Monitorização de recorrência
- Avaliação do doente
- Outros
Com base na aplicação clínica, o mercado está segmentado em rastreio de rotina, avaliação do paciente, seleção de terapêutica, monitorização de tratamento, monitorização de recorrência, entre outros.
Tecnologia
- Análise Multi-Gene-Paralela
- Análise de gene único
Com base na tecnologia, o mercado está segmentado em análise paralela multigénica e análise monogénica.
Utilizador final
- Hospitais
- Laboratórios de Referência
- Centros de diagnóstico
- Centros de Investigação e Institutos Académicos
- Outros
Com base no utilizador final, o mercado está segmentado em hospitais, laboratórios de referência, centros de diagnóstico, centros de investigação e institutos académicos, entre outros.
Canais de distribuição
- Concurso Direto
- Distribuidor Terceirizado
- Outros
Com base no canal de distribuição, o mercado está segmentado em concurso direto, distribuidor em outsourcing, entre outros.
Análise/perspetivas regionais do mercado europeu de biópsia líquida
O mercado europeu de biópsia líquida é analisado, e são fornecidos insights e tendências de tamanho de mercado com base no produto, tipo de biomaker, tipo de amostra, tipo analítico, tipo de aplicação, aplicação clínica, tecnologia, utilizador final e canal de distribuição .
Os países abrangidos neste relatório de mercado são a Alemanha, o Reino Unido, a França, a Itália, a Espanha, os Países Baixos, a Rússia, a Suíça, a Turquia, a Bélgica e o Resto da Europa.
Em 2023, prevê-se que a Alemanha domine a região da Europa devido ao aumento da prevalência e da sensibilização para o cancro.
A secção do relatório sobre países também fornece fatores individuais que impactam o mercado e alterações na regulamentação do mercado que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas, análise das cinco forças de Porter e estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas europeias e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais e o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.
Cenário competitivo e análise da quota de mercado da biópsia líquida na Europa
O panorama competitivo do mercado europeu de biópsia líquida fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença na Europa, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipeline de ensaios clínicos, análise de marca, aprovações de produtos , patentes, largura e amplitude do produto, domínio da aplicação, curva da linha de vida da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado europeu de biópsia líquida.
Alguns dos principais players do mercado europeu de biópsia líquida são a F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, mdxhealth, NeoGenomics Laboratories, Bio - Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC., Menarini Silicon Biosystems, Sysmex Inostics Inc. e ANGLE plc, entre outros.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE LIQUID BIOPSY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 INDUSTRY INSIGHTS:
6 EUROPE LIQUID BIOPSY MARKET, REGULATION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING DEMAND FOR NON-INVASIVE LIQUID BIOPSY TECHNIQUE
7.1.2 ADVANCEMENTS IN PRECISION MEDICINE DUE TO LIQUID BIOPSY
7.1.3 INCREASING CANCER PREVALENCE AND AWARENESS
7.1.4 TECHNOLOGICAL ADVANCEMENTS IN LIQUID BIOPSY PLATFORMS
7.2 RESTRAINTS
7.2.1 HIGH COST OF LIQUID BIOPSY TESTS
7.2.2 LACK OF STANDARDIZED GUIDELINES
7.3 OPPORTUNITIES
7.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING
7.3.2 INCREASING REIMBURSEMENTS AND GOVERNMENT SUPPORT FOR LIQUID BIOPSY
7.3.3 INCREASING R&D ACTIVITIES BY INSTITUTES
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS PERFORMING LIQUID BIOPSY
7.4.2 INCREASED DEPENDENCY ON OTHER BIOPSIES
8 EUROPE LIQUID BIOPSY MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 CONSUMABLES & ACCESSORIES
8.2.1 TEST KITS
8.2.1.1 TOTAL NUCLEIC ACID ISOLATION KIT
8.2.1.2 DNA ISOLATION KIT
8.2.1.3 OTHERS
8.2.2 COLLECTION TUBES
8.2.2.1 50 PIECES
8.2.2.2 100 PIECES
8.2.3 ASSAYS
8.2.3.1 FLEXIBLE REAGENTS
8.2.3.2 SCALABLE REAGENTS
8.2.3.3 OTHERS
8.2.4 CONTROL KIT
8.2.5 OTHERS
8.3 INSTRUMENTS
8.3.1 ANALYZERS
8.3.2 SYSTEMS
8.3.3 OTHERS
8.4 SERVICES & SOFTWARE
8.4.1 NGS ANALYSIS AND REPORTING SOFTWARE
8.4.2 DPCR ANALYSIS SOFTWARE
8.4.3 CASTPCR ANALYSIS SOFTWARE
8.4.4 OTHERS
9 EUROPE LIQUID BIOPSY MARKET, BY BIOMAKER TYPE
9.1 OVERVIEW
9.2 CIRCULATING TUMOR CELLS (CTCS)
9.3 CIRCULATING CELL-FREE DNA (CFDNA)
9.4 CELL-FREE RNA
9.5 EXOSOMES
9.6 EXTRACELLULAR VESICLES
9.7 OTHERS
10 EUROPE LIQUID BIOPSY MARKET, BY SAMPLE TYPE
10.1 OVERVIEW
10.2 BLOOD SAMPLE-BASED
10.3 URINE SAMPLE-BASED
10.4 SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED
10.5 OTHERS
11 EUROPE LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE
11.1 OVERVIEW
11.2 MOLECULAR
11.2.1 NGS
11.2.2 PCR
11.2.3 MICROARRAY
11.2.4 PROTEOMICS
11.2.5 OTHERS
11.3 PROTEOMIC
11.3.1 NGS
11.3.2 PCR
11.3.3 MICROARRAY
11.3.4 PROTEOMICS
11.3.5 OTHERS
11.4 HISTOLOGY/IMAGING
12 EUROPE LIQUID BIOPSY MARKET, BY APPLICATION TYPE
12.1 OVERVIEW
12.2 CANCER APPLICATIONS
12.2.1 LUNG
12.2.2 BREAST
12.2.2.1 EARLY BREAST CANCER
12.2.2.2 ADVANCED BREAST CANCER
12.2.3 COLORECTAL
12.2.4 PROSTRATE
12.2.5 LIVER
12.2.6 OTHERS
12.3 NON-CANCER APPLICATIONS
12.3.1 PRENATAL DIAGNOSIS
12.3.2 PERSONALIZED IMMUNOTHERAPY
12.3.3 OTHERS
13 EUROPE LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION
13.1 OVERVIEW
13.2 ROUTINE SCREENING
13.3 THERAPY SELECTION
13.4 TREATMENT MONITORING
13.4.1 EARLY-STAGE DISEASE
13.4.2 LATE-STAGE/METASTATIC DISEASE
13.5 RECURRENCE MONITORING
13.6 PATIENT WORK-UP
13.7 OTHERS
14 EUROPE LIQUID BIOPSY MARKET, BY TECHNOLOGY
14.1 OVERVIEW
14.2 MULTI-GENE-PARALLEL ANALYSIS
14.3 SINGLE GENE ANALYSIS
15 EUROPE LIQUID BIOPSY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 REFERENCE LABORATORIES
15.4 DIAGNOSTIC CENTERS
15.5 RESEARCH CENTERS AND ACADEMIC INSTITUTES
15.6 OTHERS
16 EUROPE LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 THIRD PARTY DISTRIBUTOR
16.4 OTHERS
17 EUROPE LIQUID BIOPSY MARKET, BY REGION
17.1 EUROPE
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 U.K.
17.1.4 ITALY
17.1.5 SPAIN
17.1.6 RUSSIA
17.1.7 TURKEY
17.1.8 BELGIUM
17.1.9 NETHERLANDS
17.1.10 SWITZERLAND
17.1.11 REST OF EUROPE
18 EUROPE LIQUID BIOPSY MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 COMPANY PROFILE
19.1 F. HOFFMANN-LA ROCHE LTD.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 GUARDANT HEALTH
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 THERMO FISHER SCIENTIFIC INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 SWOT ANALYSIS
19.3.5 PRODUCT PORTFOLIO
19.3.6 RECENT DEVELOPMENTS
19.4 EXACT SCIENCE CORPORATION
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 QIAGEN
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 ANGLE PLC (2022)
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 BIOCEPT, INC.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENT
19.8 BIO-RAD LABORATORIES, INC. (2022)
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 EPIC SCIENCES
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 FLUXION BIOSCIENCES INC
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENTS
19.11 ILLUMINA, INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 SWOT ANALYSIS
19.11.4 PRODUCT PORTFOLIO
19.11.5 RECENT DEVELOPMENT
19.12 JOHNSON & JOHNSON PRIVATE LIMITED
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 SWOT ANALYSIS
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPMENTS
19.13 LABORATORY CORPORATION OF AMERICA HOLDINGS
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 SWOT ANALYSIS
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPMENT
19.14 MDXHEALTH
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENTS
19.15 MENARINI SILICON BIOSYSTEMS
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 NATERA, INC.
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 NEOGENOMICS LABORATORIES
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 ONCOCYTE CORPORATION
19.18.1 COMPANY PROFILE
19.18.2 SERVICE PORTFOLIO
19.18.3 RECENT DEVELOPMENTS
19.19 PATHAI
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 PREDICINE
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENT
19.21 STRECK
19.21.1 COMPANY SNAPSHOT
19.21.2 PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENTS
19.22 SYSMEX INOSTICS INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tabela
TABLE 1 WAYS IN WHICH LIQUID BIOPSY HAS ADVANCED PRECISION MEDICINE
TABLE 2 EUROPE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 3 EUROPE CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 EUROPE CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 5 EUROPE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 6 EUROPE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 7 EUROPE ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 8 EUROPE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 EUROPE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 10 EUROPE SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 EUROPE SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 12 EUROPE LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 13 EUROPE CIRCULATING TUMOR CELLS (CTCS) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE CIRCULATING CELL-FREE DNA (CFDNA) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 EUROPE CELL-FREE RNA IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 EUROPE EXOSOMES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 EUROPE EXTRACELLULAR VESICLES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 EUROPE LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 20 EUROPE BLOOD SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 EUROPE URINE SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 EUROPE SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 EUROPE OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 EUROPE LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 25 EUROPE MOLECULAR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 EUROPE MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 27 EUROPE PROTEOMIC IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 EUROPE PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 29 EUROPE HISTOLOGY/IMAGING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 EUROPE LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 31 EUROPE CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 EUROPE CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 33 EUROPE BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 34 EUROPE NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 EUROPE NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 36 EUROPE LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE ROUTINE SCREENING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE THERAPY SELECTION IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 EUROPE TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 41 EUROPE RECURRENCE MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE PATIENT WORK-UP IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 EUROPE OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 EUROPE LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 45 EUROPE MULTI-GENE-PARALLEL ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE SINGLE GENE ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 EUROPE LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 48 EUROPE HOSPITALS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 EUROPE REFERENCE LABORATORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 EUROPE DIAGNOSTICS CENTERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 EUROPE RESEARCH CENTRES AND ACADEMIC INSTITUTES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 EUROPE OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 EUROPE LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 54 EUROPE DIRECT TENDER IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 EUROPE THIRD PARTY DISTRIBUTOR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 EUROPE OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 58 EUROPE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 59 EUROPE CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 60 EUROPE CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 61 EUROPE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 62 EUROPE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 63 EUROPE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 64 EUROPE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 65 EUROPE ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 66 EUROPE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 67 EUROPE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 68 EUROPE SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 69 EUROPE LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 70 EUROPE LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 71 EUROPE LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 72 EUROPE MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 73 EUROPE PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 74 EUROPE LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 75 EUROPE CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 76 EUROPE BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 77 EUROPE NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 78 EUROPE LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 79 EUROPE TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 80 EUROPE LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 81 EUROPE LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 82 EUROPE LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 83 GERMANY LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 84 GERMANY CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 GERMANY CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 86 GERMANY LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 87 GERMANY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 88 GERMANY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 89 GERMANY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 90 GERMANY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 91 GERMANY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 92 GERMANY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 93 GERMANY ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 GERMANY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 95 GERMANY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 96 GERMANY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 97 GERMANY SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 98 GERMANY LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 99 GERMANY LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 100 GERMANY LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 101 GERMANY MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 102 GERMANY PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 103 GERMANY LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 104 GERMANY CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 105 GERMANY BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 106 GERMANY NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 107 GERMANY LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 GERMANY TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 GERMANY LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 110 GERMANY LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 111 GERMANY LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 112 FRANCE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 113 FRANCE CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 114 FRANCE CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 115 FRANCE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 116 FRANCE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 117 FRANCE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 118 FRANCE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 119 FRANCE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 120 FRANCE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 121 FRANCE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 122 FRANCE ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 123 FRANCE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 124 FRANCE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 125 FRANCE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 126 FRANCE SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 127 FRANCE LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 128 FRANCE LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 129 FRANCE LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 130 FRANCE MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 131 FRANCE PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 132 FRANCE LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 133 FRANCE CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 134 FRANCE BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 135 FRANCE NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 136 FRANCE LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 137 FRANCE TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 FRANCE LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 139 FRANCE LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 140 FRANCE LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 141 U.K. LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 142 U.K. CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 143 U.K. CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 144 U.K. LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 145 U.K. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 146 U.K. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 147 U.K. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 148 U.K. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 149 U.K. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 150 U.K. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 151 U.K. ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 152 U.K. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 153 U.K. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 154 U.K. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 155 U.K. SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 156 U.K. LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 157 U.K. LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 158 U.K. LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 159 U.K. MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 160 U.K. PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 161 U.K. LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 162 U.K. CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 163 U.K. BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 164 U.K. NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 165 U.K. LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 166 U.K. TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 167 U.K. LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 168 U.K. LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 169 U.K. LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 170 ITALY LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 171 ITALY CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 172 ITALY CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 173 ITALY LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 174 ITALY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 175 ITALY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 176 ITALY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 177 ITALY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 178 ITALY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 179 ITALY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 180 ITALY ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 181 ITALY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 182 ITALY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 183 ITALY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 184 ITALY SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 185 ITALY LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 186 ITALY LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 187 ITALY LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 188 ITALY PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 189 ITALY LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 190 ITALY CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 191 ITALY BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 192 ITALY NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 193 ITALY LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 194 ITALY TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 195 ITALY LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 196 ITALY LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 197 ITALY LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 198 SPAIN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 199 SPAIN CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 200 SPAIN CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 201 SPAIN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 202 SPAIN TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 203 SPAIN TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 204 SPAIN TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 205 SPAIN COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 206 SPAIN COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 207 SPAIN COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 208 SPAIN ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 209 SPAIN INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 210 SPAIN INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 211 SPAIN INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 212 SPAIN SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 213 SPAIN LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 214 SPAIN LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 215 SPAIN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 216 SPAIN MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 217 SPAIN PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 218 SPAIN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 219 SPAIN CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 220 SPAIN BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 221 SPAIN NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 222 SPAIN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 223 SPAIN TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 224 SPAIN LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 225 SPAIN LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 226 SPAIN LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 227 RUSSIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 228 RUSSIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 229 RUSSIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 230 RUSSIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 231 RUSSIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 232 RUSSIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 233 RUSSIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 234 RUSSIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 235 RUSSIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 236 RUSSIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 237 RUSSIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 238 RUSSIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 239 RUSSIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 240 RUSSIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 241 RUSSIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 242 RUSSIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 243 RUSSIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 244 RUSSIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 245 RUSSIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 246 RUSSIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 247 RUSSIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 248 RUSSIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 249 RUSSIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 250 RUSSIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 251 RUSSIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 252 RUSSIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 253 RUSSIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 254 RUSSIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 255 RUSSIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 256 TURKEY LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 257 TURKEY CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 258 TURKEY CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 259 TURKEY LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 260 TURKEY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 261 TURKEY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 262 TURKEY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 263 TURKEY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 264 TURKEY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 265 TURKEY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 266 TURKEY ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 267 TURKEY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 268 TURKEY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 269 TURKEY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 270 TURKEY SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 271 TURKEY LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 272 TURKEY LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 273 TURKEY LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 274 TURKEY MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 275 TURKEY PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 276 TURKEY LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 277 TURKEY CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 278 TURKEY BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 279 TURKEY NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 280 TURKEY LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 281 TURKEY TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 282 TURKEY LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 283 TURKEY LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 284 TURKEY LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 285 BELGIUM LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 286 BELGIUM CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 287 BELGIUM CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 288 BELGIUM LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 289 BELGIUM TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 290 BELGIUM TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 291 BELGIUM TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 292 BELGIUM COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 293 BELGIUM COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 294 BELGIUM COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 295 BELGIUM ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 296 BELGIUM INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 297 BELGIUM INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 298 BELGIUM INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 299 BELGIUM SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 300 BELGIUM LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 301 BELGIUM LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 302 BELGIUM LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 303 BELGIUM MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 304 BELGIUM PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 305 BELGIUM LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 306 BELGIUM CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 307 BELGIUM BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 308 BELGIUM NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 309 BELGIUM LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 310 BELGIUM TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 311 BELGIUM LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 312 BELGIUM LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 313 BELGIUM LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 314 NETHERLANDS LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 315 NETHERLANDS CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 316 NETHERLANDS CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 317 NETHERLANDS LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 318 NETHERLANDS TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 319 NETHERLANDS TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 320 NETHERLANDS TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 321 NETHERLANDS COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 322 NETHERLANDS COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 323 NETHERLANDS COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 324 NETHERLANDS ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 325 NETHERLANDS INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 326 NETHERLANDS INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 327 NETHERLANDS INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 328 NETHERLANDS SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 329 NETHERLANDS LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 330 NETHERLANDS LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 331 NETHERLANDS LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 332 NETHERLANDS MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 333 NETHERLANDS PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 334 NETHERLANDS LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 335 NETHERLANDS CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 336 NETHERLANDS BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 337 NETHERLANDS NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 338 NETHERLANDS LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 339 NETHERLANDS TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 340 NETHERLANDS LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 341 NETHERLANDS LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 342 NETHERLANDS LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 343 SWITZERLAND LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 344 SWITZERLAND CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 345 SWITZERLAND CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 346 SWITZERLAND LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 347 SWITZERLAND TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 348 SWITZERLAND TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 349 SWITZERLAND TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 350 SWITZERLAND COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 351 SWITZERLAND COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 352 SWITZERLAND COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 353 SWITZERLAND ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 354 SWITZERLAND INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 355 SWITZERLAND INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 356 SWITZERLAND INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 357 SWITZERLAND SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 358 SWITZERLAND LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 359 SWITZERLAND LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 360 SWITZERLAND LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 361 SWITZERLAND MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 362 SWITZERLAND PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 363 SWITZERLAND LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 364 SWITZERLAND CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 365 SWITZERLAND BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 366 SWITZERLAND NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 367 SWITZERLAND LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 368 SWITZERLAND TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 369 SWITZERLAND LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 370 SWITZERLAND LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 371 SWITZERLAND LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 372 REST OF EUROPE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
Lista de Figura
FIGURE 1 EUROPE LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 2 EUROPE LIQUID BIOPSY MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE LIQUID BIOPSY MARKET: DROC ANALYSIS
FIGURE 4 EUROPE LIQUID BIOPSY MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE LIQUID BIOPSY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE LIQUID BIOPSY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE LIQUID BIOPSY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE LIQUID BIOPSY MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 EUROPE LIQUID BIOPSY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 11 THE GROWING DEMAND FOR NON-INVASIVE CANCER DIAGNOSTICS IS EXPECTED TO DRIVE THE EUROPE LIQUID BIOPSY MARKET GROWTH IN THE FORECAST PERIOD
FIGURE 12 CONSUMABLES & ACCESSORIES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LIQUID BIOPSY MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE LIQUID BIOPSY MARKET
FIGURE 14 ADVANTAGES OF LIQUID BIOPSY OVER TRADITIONAL BIOPSY
FIGURE 15 EUROPE LIQUID BIOPSY MARKET: BY PRODUCT, 2022
FIGURE 16 EUROPE LIQUID BIOPSY MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 17 EUROPE LIQUID BIOPSY MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 18 EUROPE LIQUID BIOPSY MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 19 EUROPE LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, 2022
FIGURE 20 EUROPE LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, 2023-2030 (USD MILLION)
FIGURE 21 EUROPE LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, CAGR (2023-2030)
FIGURE 22 EUROPE LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, LIFELINE CURVE
FIGURE 23 EUROPE LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2022
FIGURE 24 EUROPE LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)
FIGURE 25 EUROPE LIQUID BIOPSY MARKET: BY SAMPLE TYPE, CAGR (2023-2030)
FIGURE 26 EUROPE LIQUID BIOPSY MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 27 EUROPE LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2022
FIGURE 28 EUROPE LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2023-2030 (USD MILLION)
FIGURE 29 EUROPE LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, CAGR (2023-2030)
FIGURE 30 EUROPE LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, LIFELINE CURVE
FIGURE 31 EUROPE LIQUID BIOPSY MARKET: BY APPLICATION TYPE, 2022
FIGURE 32 EUROPE LIQUID BIOPSY MARKET: BY APPLICATION TYPE, 2023-2030 (USD MILLION)
FIGURE 33 EUROPE LIQUID BIOPSY MARKET: BY APPLICATION TYPE, CAGR (2023-2030)
FIGURE 34 EUROPE LIQUID BIOPSY MARKET: BY APPLICATION TYPE, LIFELINE CURVE
FIGURE 35 EUROPE LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2022
FIGURE 36 EUROPE LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
FIGURE 37 EUROPE LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, CAGR (2023-2030)
FIGURE 38 EUROPE LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, LIFELINE CURVE
FIGURE 39 EUROPE LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2022
FIGURE 40 EUROPE LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 41 EUROPE LIQUID BIOPSY MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 42 EUROPE LIQUID BIOPSY MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 43 EUROPE LIQUID BIOPSY MARKET: BY END USER, 2022
FIGURE 44 EUROPE LIQUID BIOPSY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 45 EUROPE LIQUID BIOPSY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 46 EUROPE LIQUID BIOPSY MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 EUROPE LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 48 EUROPE LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 49 EUROPE LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 50 EUROPE LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 EUROPE LIQUID BIOPSY MARKET: SNAPSHOT (2022)
FIGURE 52 EUROPE LIQUID BIOPSY MARKET: BY COUNTRY (2022)
FIGURE 53 EUROPE LIQUID BIOPSY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 54 EUROPE LIQUID BIOPSY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 55 EUROPE LIQUID BIOPSY MARKET: BY PRODUCT (2023-2030)
FIGURE 56 EUROPE LIQUID BIOPSY MARKET: COMPANY SHARE 2022 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
